Squire Patton Boggs has provided guidance to the shareholders of Dolon, a consultancy specialising in healthcare pricing and market access, regarding its acquisition by Prescient Healthcare Group. This strategic move is bolstered by the support of Prescient’s existing investor, Bridgepoint, which initially partnered with the company in 2021 through Bridgepoint Development Capital. Details pertaining to the financial aspects of the transaction remain undisclosed.
The advisory team from Squire Patton Boggs was led by Corporate partner Joe Abbott in London, with assistance from Corporate associates Isabelle Sadler and Summer Prior.
Prescient Healthcare Group is recognised as a science and insight-led partner, dedicated to the development and commercialisation of pharmaceutical and biotechnology assets. The organisation aids companies in unlocking the full potential of their offerings through the integration of extensive scientific knowledge, multi-dimensional insights, functional area expertise, and strategic acumen.
Dolon operates as a global consultancy focused on strategic pricing and market access, with particular emphasis on rare diseases and oncology. Headquartered in London and with a presence across the United States and Europe, Dolon assists biopharmaceutical companies in addressing intricate pricing, reimbursement, and access obstacles on an international scale.
This acquisition marks a significant advancement in Prescient’s growth strategy, enhancing its capacity to support global biopharmaceutical companies as they navigate the increasingly complex and interrelated clinical, commercial, and market access landscapes. Following the acquisition, Dolon will maintain its specialised focus, integrating as a dedicated Value, Pricing, and Access practice that collaborates with Prescient’s established teams.